Influence of infusion time on unchanged cisplatin disposition in patients with ovarian cancer
- 1 October 1989
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 24 (4) , 256-260
- https://doi.org/10.1007/bf00257629
Abstract
The disposition of unchanged cisplatin in ten patients with ovarian cancer receiving 2-h infusions of 100 mg/m2 was compared with that of ten patients receiving 6-h infusions. A high-performance liquid chromatographic assay specific for the unchanged drug was used and all collected samples were rapidly processed. Patients were catheterized for urine collections. Cisplatin renal clearance was significantly lower after 6-hour infusions (52.8±16.2 ml/min per m2) than after 2-h infusions (87.1±38.2 ml/min per m2) (P=0.026). Total clearance was also lower and less variable, although not significantly, in patients receiving the longer infusion. No differences in nonrenal clearance, volume of distribution, or half-life were observed between the two groups. There was only a poor relationship between cisplatin renal clearance and creatinine clearance after 2-h (r 2=0.02; P=0.66) and 6-h infusions (r 2=0.18; P=0.23). A single cisplatin plasma level obtained at the end of the infusion proved to be a good predictor of total cisplatin clearance after both 2-h (r 2-0.70; P=0.0096) and 6-h infusions (r 2=0.97; P=0.0001). This level was not significantly related to the relatively small changes in creatinine clearance that occurred after three courses of treatment.This publication has 20 references indexed in Scilit:
- Disposition of unchanged cisplatin in patients with ovarian cancerClinical Pharmacology & Therapeutics, 1987
- High-dose cisplatin in hypertonic saline: reduced toxicity of a modified dose schedule and correlation with plasma pharmacokinetics. A Northern California Oncology Group Pilot Study in non-small-cell lung cancer.Journal of Clinical Oncology, 1986
- CISPLATIN ADMINISTERED AS A CONTINUOUS 5-DAY INFUSION - PLASMA PLATINUM LEVELS AND URINE PLATINUM EXCRETION1986
- PHASE-I STUDY OF CONTINUOUS-INFUSION CISPLATIN1986
- The effect of administration rate on cisplatin-induced emesis.Journal of Clinical Oncology, 1985
- Postcolumn reaction detector for platinum(II) antineoplastic agentsAnalytical Chemistry, 1984
- Cis-diamminedichloroplatinum (II) by 5-day continuous infusion a new dose schedule with minimal toxicityCancer, 1984
- Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implicationsEuropean Journal of Cancer and Clinical Oncology, 1982
- PHASE I STUDY OF CIS-DIAMMINEDICHLOROPLATINUM(II) ADMINISTERED AS A CONSTANT 5-DAY INFUSION1980
- Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusionCancer Chemotherapy and Pharmacology, 1980